“The Value and Sustainability of Ocrelizumab in Relapsing Multiple Sclerosis: A Cost-Effectiveness and Budget Impact Analysis”. Farmeconomia. Health economics and therapeutic pathways 20, no. 1 (July 10, 2019). Accessed October 29, 2025. https://journals.seedstm.com/index.php/FE/article/view/1435.